Alpelisib plus fulvestrant in PIK3CA-Altered and PIK3CA-wild-type estrogen receptor–positive advanced breast cancer: A phase 1b clinical trial
<p><strong>Importance</strong> The phosphatidylinositol 3-kinase (PI3K) pathway is frequently activated in patients with estrogen receptor–positive (ER+), endocrine therapy–resistant breast cancers.</p> <p><strong>Objective</strong> To assess the maximum t...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Published: |
American Medical Association
2018
|